$EOLS
Evolus Inc Stock $eols

$eols Overview Financials Valuation SEC Filings Company Website

2018 Q3 Form 10-Q Financial Statement

#000157056218000100 Filed on August 02, 2018

Income Statement

Concept	2018 Q3	2018 Q2	2017 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue	$0.00	$0.00
YoY Change
Gross Profit	$0.00	$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.209M	$6.248M	$800.0K
YoY Change	526.87%	681.0%
% of Gross Profit
Research & Development	$1.977M	$1.648M	$1.365M
YoY Change	34.95%	20.73%
% of Gross Profit
Depreciation & Amortization	$3.000K	$0.00	$110.0K
YoY Change		-100.0%	-8.33%
% of Gross Profit
Operating Expenses	$11.49M	$16.10M	$2.275M
YoY Change	339.18%	607.69%
Operating Profit	-$11.49M	-$16.10M	-$2.275M
YoY Change	339.18%	607.69%
Interest Expense	-$320.0K	-$320.0K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$322.0K	-$321.0K	-$1.000K
YoY Change	16000.0%	32000.0%
Pretax Income	-$11.81M	-$16.42M	-$2.276M
YoY Change	351.15%	621.49%
Income Tax	$19.00K	$12.00K	$20.00K
% Of Pretax Income
Net Earnings	-$11.83M	-$16.43M	-$2.296M
YoY Change	355.0%	615.72%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$477.6K	-$693.5K	-$97.50K
COMMON SHARES
Basic Shares Outstanding	26.67M shares	23.64M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q3	2018 Q2	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$105.2M	$43.60M	$0.00
YoY Change
Cash & Equivalents	$105.2M	$43.60M	$0.00
Short-Term Investments
Other Short-Term Assets	$900.0K	$1.000M	$100.0K
YoY Change	200.0%	900.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$106.1M	$44.62M	$100.0K
YoY Change	35264.0%	44523.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.000K	$5.000K
YoY Change
Goodwill	$21.21M	$21.21M
YoY Change
Intangibles	$56.08M	$56.08M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$22.00K	$200.0K
YoY Change	-100.0%	-89.0%
Total Long-Term Assets	$77.29M	$77.31M	$146.0M
YoY Change	-48.72%	-47.05%
TOTAL ASSETS
Total Short-Term Assets	$106.1M	$44.62M	$100.0K
Total Long-Term Assets	$77.29M	$77.31M	$146.0M
Total Assets	$183.4M	$121.9M	$146.1M
YoY Change	21.44%	-16.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$661.0K	$751.0K	$500.0K
YoY Change	120.33%	50.2%
Accrued Expenses	$4.799M	$2.933M	$300.0K
YoY Change	499.88%	877.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$68.60M
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$5.460M	$3.684M	$69.40M
YoY Change	-92.54%	-94.69%
LONG-TERM LIABILITIES
Long-Term Debt	$16.80M	$16.50M	$122.4M
YoY Change	-87.55%	-86.52%
Other Long-Term Liabilities	$51.10M	$48.80M	$0.00
YoY Change
Total Long-Term Liabilities	$67.90M	$65.30M	$122.4M
YoY Change	-49.67%	-46.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.460M	$3.684M	$69.40M
Total Long-Term Liabilities	$67.90M	$65.30M	$122.4M
Total Liabilities	$88.41M	$84.00M	$213.1M
YoY Change	-61.48%	-60.58%
SHAREHOLDERS EQUITY
Retained Earnings	-$110.6M	-$98.75M
YoY Change
Common Stock	$1.000K	$1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$94.97M	$37.93M	-$67.00M
YoY Change
Total Liabilities & Shareholders Equity	$183.4M	$121.9M	$146.1M
YoY Change	21.44%	-16.54%

Cashflow Statement

Concept	2018 Q3	2018 Q2	2017 Q2
OPERATING ACTIVITIES
Net Income	-$11.83M	-$16.43M	-$2.296M
YoY Change	355.0%	615.72%
Depreciation, Depletion And Amortization	$3.000K	$0.00	$110.0K
YoY Change		-100.0%	-8.33%
Cash From Operating Activities	-$5.800M	-$5.660M	-$3.210M
YoY Change	69.1%	76.32%	-63.69%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$10.00K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$10.00K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$67.68M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	67.38M	-310.0K	3.220M
YoY Change	1864.43%	-109.63%	-63.57%
NET CHANGE
Cash From Operating Activities	-5.800M	-5.660M	-3.210M
Cash From Investing Activities	0.000	-10.00K	0.000
Cash From Financing Activities	67.38M	-310.0K	3.220M
Net Change In Cash	61.58M	-5.980M	10.00K
YoY Change	-3306051076096000000.0%	-59900.0%
FREE CASH FLOW
Cash From Operating Activities	-$5.800M	-$5.660M	-$3.210M
Capital Expenditures	$0.00	-$10.00K	$0.00
Free Cash Flow	-$5.800M	-$5.650M	-$3.210M
YoY Change	69.1%	76.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	eols	Revaluationof Contingent Royalty Obligation Payableto Related Party RevaluationofContingentRoyaltyObligationPayabletoRelatedParty	9100000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	40000	USD
	eols	Non Cash Related Party Borrowings NonCashRelatedPartyBorrowings	68767000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	22000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001570562
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	26674991	shares
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	EVOLUS, INC.
	dei	Trading Symbol TradingSymbol	EOLS
	eols	Accounts Payable Paidby Parent AccountsPayablePaidbyParent	0	USD
	eols	Accounts Payable Paidby Parent AccountsPayablePaidbyParent	163000	USD
	eols	Business Combination Liquidated Damages BusinessCombinationLiquidatedDamages	1000000	USD
	eols	Business Combination Periodin Which Liquidated Damageswillbe Awarded BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded	P30D
	eols	Capital Contribution Convertible Note Write Off CapitalContributionConvertibleNoteWriteOff	0	USD
	eols	Capital Contribution Convertible Note Write Off CapitalContributionConvertibleNoteWriteOff	66998000	USD
	eols	Capital Contribution Forgivenessof Related Party Borrowings CapitalContributionForgivenessofRelatedPartyBorrowings	0	USD
	eols	Capital Contribution Forgivenessof Related Party Borrowings CapitalContributionForgivenessofRelatedPartyBorrowings	13188000	USD
	eols	Contingent Promissory Note ContingentPromissoryNote	0	USD
	eols	Contingent Promissory Note ContingentPromissoryNote	16042000	USD
	eols	Contingent Royalty Obligation ContingentRoyaltyObligation	0	USD
	eols	Contingent Royalty Obligation ContingentRoyaltyObligation	39700000	USD
	eols	Deferred Ipo Costs DeferredIPOCosts	0	USD
	eols	Deferred Ipo Costs DeferredIPOCosts	2885000	USD
	eols	Deferred Offering Costs Unpaid DeferredOfferingCostsUnpaid	0	USD
	eols	Deferred Offering Costs Unpaid DeferredOfferingCostsUnpaid	22000	USD
	eols	Non Cash Capital Distribution From Parent NonCashCapitalDistributionFromParent	53854000	USD
	eols	Non Cash Capital Distribution From Parent NonCashCapitalDistributionFromParent	0	USD
	eols	Non Cash Note Obligation NonCashNoteObligation	-122437000	USD
	eols	Non Cash Note Obligation NonCashNoteObligation	140688000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4016000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	89000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	854000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3630000	USD
	eols	Non Cash Related Party Borrowings NonCashRelatedPartyBorrowings	0	USD
	eols	Non Cash Related Party Receivable NonCashRelatedPartyReceivable	-68583000	USD
	eols	Non Cash Related Party Receivable NonCashRelatedPartyReceivable	73690000	USD
CY2017Q2	eols	Revaluationof Contingent Royalty Obligation Payableto Related Party RevaluationofContingentRoyaltyObligationPayabletoRelatedParty	0	USD
	eols	Revaluationof Contingent Royalty Obligation Payableto Related Party RevaluationofContingentRoyaltyObligationPayabletoRelatedParty	0	USD
CY2017	eols	Tax Cuts And Jobs Act Incomplete Accounting Change In Tax Rate Deferred Tax Liability Provisional Income Tax Benefit TaxCutsAndJobsActIncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxBenefit	6300000	USD
CY2018Q2	eols	Revaluationof Contingent Royalty Obligation Payableto Related Party RevaluationofContingentRoyaltyObligationPayabletoRelatedParty	8200000	USD
CY2017	eols	Tax Cutsand Jobs Actof2017 Incomplete Accounting Changein Tax Rate Provisional Decreasein Net Deferred Tax Assets TaxCutsandJobsActof2017IncompleteAccountingChangeinTaxRateProvisionalDecreaseinNetDeferredTaxAssets	3200000	USD
CY2017Q4	eols	Tax Cutsand Jobs Actof2017 Incomplete Accounting Changein Tax Rate Provisional Decreasein Valuation Allowance TaxCutsandJobsActof2017IncompleteAccountingChangeinTaxRateProvisionalDecreaseinValuationAllowance	9600000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	445000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	751000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	977000	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2933000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	0	USD
CY2018Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	136687000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	246000	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2623000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3630000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3600000	USD
CY2017Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2018Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1084000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2906000	shares
CY2017Q4	us-gaap	Assets Assets	152233000	USD
CY2018Q2	us-gaap	Assets Assets	121934000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	72824000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	44623000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	9100000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43585000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43600000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	187000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43585000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-187000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	43585000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16527000	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23674991	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16527000	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23674991	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	1000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	40000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2296000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6294000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16433000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22595000	USD
CY2017Q4	us-gaap	Contractual Obligation ContractualObligation	0	USD
CY2018Q2	us-gaap	Contractual Obligation ContractualObligation	48800000	USD
CY2018Q1	us-gaap	Contractual Obligation ContractualObligation	40600000	USD
CY2018Q2	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	2900000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	14990000	USD
CY2018Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	15013000	USD
CY2017Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	2100000	USD
CY2018Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	22000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	38000	USD
CY2018Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	32000	USD
CY2017Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	107000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	218000	USD
CY2018Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	218000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4000	USD
CY2017	us-gaap	Dividends Dividends	66100000	USD
CY2017Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	72639000	USD
CY2018Q2	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	0	USD
CY2017Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	72639000	USD
CY2018Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.69
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.03
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	803000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2018000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6248000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9715000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	21208000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	21200000	USD
CY2018Q2	us-gaap	Goodwill Goodwill	21208000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	21200000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2276000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6254000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16421000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22573000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	12000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22000	USD
CY2017Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	56100000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2346000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	471000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-408000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1935000	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-2000	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-5000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	157000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2018Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	56100000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	56076000	USD
CY2018Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	56076000	USD
	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	428000	USD
CY2017Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	38000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	79000	USD
CY2018Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	66000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	118000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	227776000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	83999000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	152233000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	121934000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	212748000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3684000	USD
CY2017Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2018Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	16470000	USD
CY2018Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	16100000	USD
CY2017Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
CY2018Q2	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8605000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	51458000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8800000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8792000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7864000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7900000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-2300000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-2296000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-6294000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-6300000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-16400000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-16433000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22595000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22600000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	2275000	USD
CY2017Q4	us-gaap	Notes Payable Current NotesPayableCurrent	138687000	USD
CY2017Q4	us-gaap	Notes Payable Current NotesPayableCurrent	138700000	USD
CY2018Q2	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	unit
	us-gaap	Operating Expenses OperatingExpenses	6252000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	16100000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	364000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	74000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	175000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	115000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2125000	USD
	us-gaap	Operating Expenses OperatingExpenses	22145000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2275000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6252000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-16100000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22145000	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	22000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-321000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-428000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	760000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	239000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	185000	USD
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1038000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	56300000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	56300000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	56330000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	8605000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1127000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5000	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	5000000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1365000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1648000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3326000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-75543000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98800000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98753000	USD
CY2018Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	12.00
CY2018Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	12.00
	us-gaap	Share Based Compensation ShareBasedCompensation	246000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	102835
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	4361291	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1496005	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1570145	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.04
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.70
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.98
CY2018Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.85
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-75543000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	37935000	USD
CY2018Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1.6527
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16527000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16527000	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23687866	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21961576	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Risk and Uncertainties</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has not commenced principal operations in the form of commercialized Product sales. The Product requires regulatory approval from the U.S. Food and Drug Administration (“FDA”), the European Medicines Agency, and other similar regulatory authorities prior to commercial sales. The Company’s current and any future product candidates may not receive the necessary approvals. If the Company is denied approval or approval is delayed, it may have a material adverse impact on the Company’s business and its financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is subject to risks common to early stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of its current and any future product candidates, ability to obtain regulatory approval of its current and any future product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-style:normal;font-weight:normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. Actual results could materially differ from those estimates, judgments, and assumptions. Management considers many factors in selecting appropriate financial accounting policies and controls and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates</font><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On an ongoing basis, the Company evaluates the most significant estimates, including those related to the fair values of financial instruments, intangible assets and goodwill, useful lives of intangible assets, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">royalty obligations, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">among others. Although the Company bases these estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments over the carrying values of assets and liabilities, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</font></div></div>

Files In Submission

Name	View Source	Status
0001570562-18-000100-index-headers.html	Edgar Link	pending
0001570562-18-000100-index.html	Edgar Link	pending
0001570562-18-000100.txt	Edgar Link	pending
0001570562-18-000100-xbrl.zip	Edgar Link	pending
eols-20180630.xml	Edgar Link	completed
eols-20180630.xsd	Edgar Link	pending
eols-20180630_cal.xml	Edgar Link	unprocessable
eols-20180630_def.xml	Edgar Link	unprocessable
eols-20180630_lab.xml	Edgar Link	unprocessable
eols-20180630_pre.xml	Edgar Link	unprocessable
evolus06301810-q.htm	Edgar Link	pending
exhibit31106301810q.htm	Edgar Link	pending
exhibit31206301810q.htm	Edgar Link	pending
exhibit32106301810q.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EOLS
Evolus Inc Stock $eols

2018 Q3 Form 10-Q Financial Statement

#000157056218000100 Filed on August 02, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EOLS Evolus Inc Stock $eols

2018 Q3 Form 10-Q Financial Statement

#000157056218000100 Filed on August 02, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EOLS
Evolus Inc Stock $eols